Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

The stock has been fairly stable over the past year.

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its ...

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

Pfizer is almost certain to survive the current headwinds as a business. However, the dividend may not. It will be important ...

The company expects to launch more than 20 pivotal late-stage trials this year.

Pfizer India's shares surged after reporting strong Q3FY26 results, with net profit up 11% and revenue by 20%. The company ...